Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Aristeia Capital L.L.C.

Key Points

• Aristeia Capital L.L.C. reduced its stake in Amphastar Pharmaceuticals by 21.7%, selling 9,400 shares during the first quarter, leaving it with 33,835 shares valued at approximately $981,000.
• Amphastar Pharmaceuticals’ stock opened at $29.42 and has seen a 12-month range between $20.39 and $53.96, with a current market capitalization of $1.37 billion.
• Recent analyst ratings for Amphastar Pharmaceuticals include a target price increase to $32.00 from Bank of America, while Piper Sandler lowered its target price to $25.00, reflecting mixed sentiment among analysts.

Aristeia Capital L.L.C. trimmed its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 21.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,835 shares of the company's stock after selling 9,400 shares during the quarter. Aristeia Capital L.L.C. owned 0.07% of Amphastar Pharmaceuticals worth $981,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Amphastar Pharmaceuticals by 4,151.3% during the 1st quarter. GAMMA Investing LLC now owns 38,644 shares of the company's stock worth $1,120,000 after buying an additional 37,735 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in Amphastar Pharmaceuticals by 14.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company's stock worth $400,000 after buying an additional 1,694 shares during the last quarter. Deutsche Bank AG grew its stake in Amphastar Pharmaceuticals by 46.6% during the 4th quarter. Deutsche Bank AG now owns 34,082 shares of the company's stock worth $1,265,000 after buying an additional 10,839 shares during the last quarter. Picton Mahoney Asset Management grew its stake in Amphastar Pharmaceuticals by 6,600.0% during the 1st quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company's stock worth $46,000 after buying an additional 1,584 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in Amphastar Pharmaceuticals by 27.2% during the 4th quarter. ProShare Advisors LLC now owns 13,852 shares of the company's stock worth $514,000 after buying an additional 2,958 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AMPH. Piper Sandler dropped their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research note on Friday, August 8th. Bank of America boosted their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research note on Tuesday, August 26th. Finally, Needham & Company LLC upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target on the stock in a research note on Tuesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $31.60.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock traded down $0.62 on Friday, hitting $28.06. The company had a trading volume of 273,491 shares, compared to its average volume of 409,880. The firm has a market cap of $1.30 billion, a P/E ratio of 10.51 and a beta of 0.80. The company has a 50-day moving average price of $25.76 and a 200-day moving average price of $25.65. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $53.96.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.